image-20200420214112-3

You may have missed

Reviva Announces Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in Schizophrenia

EPKINLYTM (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

MAR Weekly Report_VIRBAC SA_18 to 22 September 2023

Tenapanor for Hyperphosphatemia Approved in Japan

Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®

error: Content is protected !!